版本:
中国

BRIEF-Merck provides update on supplemental biologics license application (sbla) for KEYTRUDA® (pembrolizumab)

March 14 Merck & Co Inc

* Merck provides update on supplemental biologics license application (sbla) for keytruda® (pembrolizumab) in previously treated advanced microsatellite instability-high cancer

* Merck & co inc - new fda target action date is june 9, 2017

* Merck & co-submission of additional data is considered major amendment to sbla under pdufa, thus extending target action date by three months Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐